4D Molecular Therapeutics (FDMT) Capital Expenditures (2020 - 2026)

4D Molecular Therapeutics (FDMT) has reported Capital Expenditures for 6 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Capital Expenditures rose 355.32% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.8 million (up 48.85% YoY), while the FY2025 annual figure was $4.9 million, up 30.14% from the prior year.
• Capital Expenditures grew to $4.3 million in Q4 2025 per FDMT's latest filing, from -$91000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $6.4 million in Q1 2022 and bottomed at -$8.0 million in Q3 2022.
• Historically, Capital Expenditures has averaged $903400.0 across 5 years, with a median of $633500.0 in 2024.
• Annual changes were most pronounced in 2022 — Capital Expenditures surged 4322.76% — and 2023, when it sank 351.82%.
• 4D Molecular Therapeutics' Capital Expenditures stood at $5.1 million in 2021, then plunged by 108.63% to -$440000.0 in 2022, then tumbled by 351.82% to -$2.0 million in 2023, then surged by 147.74% to $949000.0 in 2024, then soared by 355.32% to $4.3 million in 2025.
• Business Quant data shows FDMT's Capital Expenditures at $4.3 million in Q4 2025, -$91000.0 in Q3 2025, and $557000.0 in Q2 2025.